PCT & Support

Anastrozole 1 mg Somatrop-Lab

Somatrop-Lab

70,00

In Stock (100 available)

Anastrozole 1 mg Somatrop-Lab (1 mg) — As a third-generation aromatase inhibitor, Anastrozole offers advantages over both first-generation AIs and SERMs: faster onset of…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

This Somatrop-Lab anastrozole at 1 mg blocks aromatase competitively; unlike exemestane‘s suicide inhibition, effects are reversible. Monitor E2 every 4 weeks during use.

Key Benefits

  • Aromatase inhibitor — blocks oestrogen synthesis at the source
  • Standard on-cycle AI for testosterone-based protocols
  • Low dose (0.25–0.5 mg EOD) typically sufficient for 400–500 mg test
  • Dose by bloodwork — sensitive E2 assay, target 20–40 pg/mL
  • Crashing E2 feels worse than mildly elevated E2 — err on the low side
  • Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 0.25–0.5 mg every other day on testosterone-based cycles. Titrate to bloodwork (sensitive E2 assay, target 20–40 pg/mL). Higher doses required only on aggressive 700+ mg/week test protocols. During PCT: not used (blocks oestrogen needed for LH signalling).

How It Works

Non-steroidal aromatase inhibitor. Binds and inactivates the aromatase enzyme (CYP19A1) that converts testosterone and androstenedione to estradiol and estrone. Reversible binding — effect disappears within days of stopping.

Potential Side Effects

Primary risk: crashed E2 — joint pain, low libido, lethargy, brain fog. If these appear, drop dose immediately. Lipid impact modest. No hepatic toxicity.

Pharmacokinetics

Plasma half-life approximately 50 hours. Every-other-day dosing produces stable serum and tissue levels. Steady-state in 7 days.

Cycle & Stacking Guide

Used on-cycle with aromatising compounds (testosterone, methandienone, oxymetholone). Start at 0.25 mg EOD, bloodwork at week 4, adjust. Never used during PCT — needed estrogen signalling for LH/FSH recovery.

Manufacturer Notes

Somatrop-Lab specialises in growth-hormone and peptide products with lyophilised format and strict cold-chain documentation.

Storage & Handling

Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Anastrozole 1 mg Somatrop-Lab”

Your email address will not be published. Required fields are marked *

Anastrozole

Physical & Chemical Properties for Research Purposes
Chemical structure of Anastrozole (C17H19N5) for laboratory analysis
2D structural representation · PubChem CID 2187 ↗
Chemical Identity
# CAS Registry Number 120511-73-1
Σ IUPAC Name 2-[5-(1H-1,2,4-triazol-1-ylmethyl)-2-methylphenyl]-2-methylpropanenitrile
F Molecular Formula C17H19N5
M Molecular Weight 293.37 g/mol
SMILES CC1=CC(=CC(=C1)C(C)(C)C#N)CN2C=NC=N2
InChIKey YBBLVLTVTVKRGT-UHFFFAOYSA-N
Melting Point 81-82 °C
Solubility Freely soluble in methanol, acetone; very slightly soluble in water
Biological Half-life 40-50 hours (oral)
PubChem CID 2187 ↗
Pharmacological Profile
Aromatization None
Hepatotoxicity Low

Clinical Notes

Third-generation non-steroidal aromatase inhibitor — competitive binding to CYP19A1 without receptor degradation. Dose-response is steep and individual: 0.25 mg twice weekly is a functional starting point on 500 mg/week testosterone protocols; 1 mg doses reliably crash E2 below physiological threshold in the majority of lean subjects. Half-life of 48 hours allows twice-weekly dosing. Clinical error pattern: aggressive preemptive dosing produces the hypoestrogenaemic profile (arthralgia, cognitive dulling, lipid degradation, libido crash) faster than a gradual increase ever produces gyno. Correct sequencing: bloodwork at week 4–5 of cycle, dose to measured E2 value, retest after 3 weeks. AI-free protocols are clinically viable for low-aromatiser users.

Known trade names: Arimidex, Anastrol, Armotraz

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.